SHANGHAI, April 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in ...

Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

To address this challenge, CTMC has established a patient material bank, enabling early-stage process development with clinically relevant samples. This resource also supports continuous process ...

CD8-positive T cells are a critical subpopulation of MHC class I-restricted T cell and are mediators of adaptive immunity. They include cytotoxic T cells, which are important for killing cancerous ...

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it. After treatment with CAR-T ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

These lymphocytes, including B cells, CD4+ T cells (helper T cells), CD8+ T cells (cytotoxic T cells), and natural killer (NK) cells, play crucial roles in the immune system. The test helps assess ...

Dragonfly's TriNKET compounds are designed to activate and direct NK and cytotoxic T cell killing against cancer cells. The platform has also attracted partnerships from other pharma groups ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners ... data on the logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid ...